BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25042117)

  • 1. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
    Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
    Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and correlates of prostate cancer treatment in older men.
    Roberts CB; Albertsen PC; Shao YH; Moore DF; Mehta AR; Stein MN; Lu-Yao GL
    Am J Med; 2011 Mar; 124(3):235-43. PubMed ID: 21396507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.
    Boehm K; Dell'Oglio P; Tian Z; Capitanio U; Chun FKH; Tilki D; Haferkamp A; Saad F; Montorsi F; Graefen M; Karakiewicz PI
    World J Urol; 2017 Jul; 35(7):1031-1036. PubMed ID: 27796538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Palvolgyi R; Dash A; Greenfield S; Litwin MS
    Cancer; 2011 May; 117(10):2058-66. PubMed ID: 21523717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
    Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
    World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life Expectancy and Variation in Treatment for Early Stage Kidney Cancer.
    Daskivich TJ; Tan HJ; Litwin MS; Hu JC
    J Urol; 2016 Sep; 196(3):672-7. PubMed ID: 27012644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
    Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
    J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    Huang H; Muscatelli S; Naslund M; Badiyan SN; Kaiser A; Siddiqui MM
    J Urol; 2019 Jan; 201(1):120-128. PubMed ID: 30059685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
    Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.
    Wong AT; Safdieh JJ; Rineer J; Weiner J; Schwartz D; Schreiber D
    Int Urol Nephrol; 2015 Oct; 47(10):1629-34. PubMed ID: 26329748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued undertreatment of older men with localized prostate cancer.
    Schwartz KL; Alibhai SM; Tomlinson G; Naglie G; Krahn MD
    Urology; 2003 Nov; 62(5):860-5. PubMed ID: 14624909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of advanced treatment technologies among men at low risk of dying from prostate cancer.
    Jacobs BL; Zhang Y; Schroeck FR; Skolarus TA; Wei JT; Montie JE; Gilbert SM; Strope SA; Dunn RL; Miller DC; Hollenbeck BK
    JAMA; 2013 Jun; 309(24):2587-95. PubMed ID: 23800935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.